Closed $110M Pre‑IPO financing (approx. RMB 780M), Co‑led by VIVO Capital, Beijing Medical & Health Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund.
Since its founding, the company has completed over $300 million in five rounds of private financing, backed by top-tier global VC/PE life‑science funds and sovereign wealth investors.
Closed $110M Pre‑IPO financing (approx. RMB 780M), Co‑led by VIVO Capital, Beijing Medical & Health Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund.
Completed series B1 round totaling $45M USD, co-led by RTW Investments and Qatar Investment Authority
Completed series B financing totaling $120M USD, co-led by Qiming Venture Partners and Quan Capital
Raised ¥202M RMB (~$30M USD) ,
led by Yijing Capital
Received pre-A round of exclusive funding of ¥80M RMB (~$12M USD) from Qiming Venture Partners
Founded with a capital of ¥100M RMB(~$14M)
RTW Investments, LP, headquartered in New York with offices in Shanghai and London, is a global life sciences investment and innovation firm focused on transformative and disruptive innovative technologies in the biopharmaceutical and medical technology sectors.
RTW Investments, LP, headquartered in New York with offices in Shanghai and London, is a global life sciences investment and innovation firm focused on transformative and disruptive innovative technologies in the biopharmaceutical and medical technology sectors. As a leading partner to industry and academia, RTW combines deep scientific expertise with a solutions-oriented investment approach to advance emerging medical therapies through companies or academic institutions that it builds, supports and empowers.
More information, please visit www.rtwfunds.com
Qatar Investment Authority ("QIA") is the sovereign wealth fund of the State of Qatar.QIA was established in 2005 to invest and manage the National Reserve Fund. QIA is one of the largest and most active sovereign wealth funds in the world.
Qatar Investment Authority ("QIA") is the sovereign wealth fund of the State of Qatar.QIA was established in 2005 to invest and manage the National Reserve Fund. QIA is one of the largest and most active sovereign wealth funds in the world. QIA invests in a wide range of asset classes and regions, and partners with leading institutions around the world to QIA invests in a wide range of asset classes and regions, and partners with leading institutions around the world to build a globally diversified portfolio with a long-term outlook to achieve sustainable returns and contribute to the prosperity of the State of Qatar.
More information, please visit https://www.qia.qa.
Qiming Venture Partners, founded in 2006, is currently managing 7 phases of USD funds and 5 phases of RMB funds. The total assets under its management are more than 4 billion USD.
Qiming Venture Partners, founded in 2006, is currently managing 7 phases of USD funds and 5 phases of RMB funds. The total assets under its management are more than 4 billion USD. Qiming Venture Partners focuses on investing in exceptional firms in the TMT and Healthcare fields at the start-up and growth stages. Since its founding, Qiming Venture Partners has been highly acknowledged for its outstanding investment performance by investors from China and all over the world and has become a top-choice investment institution for entrepreneurs. Qiming Venture Partners has risen to the top in many reputable rankings of China's venture capital business. It has collaborated with many excellent high-tech entrepreneurs to create unicorn and listed enterprises.
More information, please visit https://www.qimingvc.com
Quan Capital is a venture capital fund focusing on early-stage and growth-stage life science companies.
Quan Capital is a venture capital fund focusing on early-stage and growth-stage life science companies. Driven by innovation and guided by unique scientific and commercial insights, it seeks, creates, and invests in fast-growing life sciences leaders around the world. Companies in the current portfolio include companies with innovative therapies, cutting-edge technology platforms, and industry leaders that fill gaps in the ecosystem. Quan Capital currently has offices in Shanghai, San Francisco and Boston.
More information, please visit https://www.quancapital.com
C&D Emerging Industry Equity Investment is an enterprise-level venture capital institution supported by the C&D Group, a Fortune 500 enterprise.
C&D Emerging Industry Equity Investment is an enterprise-level venture capital institution supported by the C&D Group, a Fortune 500 enterprise. Founded in 2014, the company carries out the mission of "exploring new values and helping more growth-type new-economy enterprises achieve better development". C&D Emerging Industry Equity Investment focuses on new economy sectors such as healthcare, advanced manufacturing, and TMT/consumption.
More information, please visit https://www.jianfacapital.com
Founded in 2012 by the former management team of Sinopharm, Jianyi Capital focuses on early stage and growth stage equity investments in the pharmaceutical and healthcare sectors.
Founded in 2012 by the former management team of Sinopharm, Jianyi Capital focuses on early stage and growth stage equity investments in the pharmaceutical and healthcare sectors. With a fund size of over RMB 6.5 billion, the firm has invested in more than 80 leading companies in sector, covering early-stage innovation, growth and M&A integration projects. With the philosophy of "Sincerity, Professionalism and Win-Win", Jianyi Capital has always accompanied the growth of invested companies, combining the market-oriented advantages of CVC strategic investment and independent VC funds with its own industrial resources to continuously empower the invested companies.
Founded in 2021 by the Suzhou fund management team, the fund was established in BioBAY Biomedical Industrial Park.
Founded in 2021 by the Suzhou fund management team, the fund was established in BioBAY Biomedical Industrial Park. Relying on Suzhou's strong biomedical industry and favorable environment for entrepreneurship and innovation, the fund focuses on the medical and healthcare industry and the fields of biomedicine and medical devices. Suzhou Jinlin Fund is committed to becoming a dedicated, professional and market-recognized fund that provides comprehensive support and services for enterprise growth, and contributes to the development of China's medical and healthcare industry with a steady stream of financial power.
Adhering to the concept of long-term value investment, Boquan Capital focuses on investments in the medical and healthcare field, and is committed to finding and supporting potential early-stage and growth-stage companies, transforming accumulated resources into empowerment for companies and growing together.
Adhering to the concept of long-term value investment, Boquan Capital focuses on investments in the medical and healthcare field, and is committed to finding and supporting potential early-stage and growth-stage companies, transforming accumulated resources into empowerment for companies and growing together. Boquan Capital has investments in various fields including biopharmaceuticals, medical devices, healthcare services, and diagnostics.
A market-oriented mother fund initiated and established by Shanghai International Group, with assets under management of over 12 billion RMB. It focuses on strategic emerging industries such as next-generation information technology, biomedicine, advanced manufacturing and green energy.
A market-oriented mother fund initiated and established by Shanghai International Group, with assets under management of over 12 billion RMB. It focuses on strategic emerging industries such as next-generation information technology, biomedicine, advanced manufacturing and green energy. The direct investment fund mainly covers early-stage and growth-stage science and technology enterprises that are in line with the national strategy, with leading technology and originality, with outstanding import substitution effect under the two-cycle pattern, and with unicorn potential.
Origincell Group is the founding shareholder of Oricell Therapeutics, which was jointly established in 2014 by Canature Health (300272), a GEM-listed company, and its founder, Mr. Qu Jianguo.
Origincell Group is the founding shareholder of Oricell Therapeutics, which was jointly established in 2014 by Canature Health (300272), a GEM-listed company, and its founder, Mr. Qu Jianguo. With a first-phase investment of 1.5 billion yuan, Origincell has built three industrial parks covering an area of 80 acres and having a construction area of nearly 100,000 square meters in the core zone of Zhangjiang Science City. These three industrial parks have also attracted many other biomedical innovation enterprises with great potentials. Origincell also owns the following subsidiaries: Origincell Biological Cryo Equipment Co., Ltd., specialized in R&D and production of cell cryopreservation equipment; Yuantian Biotechnology Co., Ltd., specialized in stem cell and exosome research and cell preparation and culture services; Origincell-Bank Co., Ltd., specialized in automated and intelligent cell preservation services. These subsidiaries constitute a complete industrial chain. The total number of patents applied by the Origincell has exceeded 300, which indicates stable development and bright prospects.
More information, please visit https://www.origincell.com
Yijing Capital, founded in 2015, is mainly engaged in primary market equity investment and fund of funds (FOF) investment using its own funds and privately offered funds.
Yijing Capital, founded in 2015, is mainly engaged in primary market equity investment and fund of funds (FOF) investment using its own funds and privately offered funds. Adhering to the concept of "helping enterprises innovate and grow, promoting industrial optimization and upgrading, and boosting social development and progress", Yijing Capital focuses on areas including big health industry, TMT & big consumption, and hard and core technology. It is specialized in investing in high-value high-tech innovative enterprises at their start-up and growth stages. As to the medical field, Yijing Capital has invested in many industry-leading enterprises, including Leto Laboratories, Our United Corp., Hanyu Medical, SS Innovations, WELLEM Pediatrics, and MedSci.
More information, please visit https://www.yijingcapital.com
沪公网安备 31011502019994号